© 2022 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.
Type II Inflammation
Early Identification of CRSwNP Recurrence After Surgery Possible With Regular Follow-Up Exams
November 11, 2022
Adherence to follow-up examinations is crucial for early identification of recurrence of chronic rhinosinusitis with nasal polyps (CRSwNP).
Characteristics of EoE Differ Among Those With Childhood- and Adult-Onset Disease
November 10, 2022
Despite differing characteristics, patients have similar responses to treatment regardless of when they were diagnosed with eosinophilic esophagitis (EoE).
Dupixent Reduced Symptom Burden in Patients With CRSwNP Over 52 Weeks
November 07, 2022
Symptoms of chronic rhinosinusitis with nasal polyps can be a burden for patients, but Dupixent was able to successfully reduce the number of days with severe symptoms.
Real-World Study Shows Dupixent Improves AD Symptoms in Children Under 12 Years
October 05, 2022
A real-world study of children with moderate-to-severe atopic dermatitis (AD) in China found Dupixent can reduce symptoms and improve pruritus. Traditional therapies had little effect, according to the researchers.
More Than Half of Patients With EoE Successfully Respond to Dietary Elimination
October 05, 2022
A sizable majority (69%) of eosinophilic esophagitis (EoE) patients only had one food trigger.
Guidelines Mostly Overlap on Recommendation of Using Biologics for CRSwNP
October 05, 2022
The majority of guidelines and recommendations available limit biologics to cases of severe and uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP) and require prior surgery.
Extension Trial Shows Positive Results for Dupixent
September 07, 2022
Results reported at a meeting of the European Respiratory Society this week show a low rate of severe asthma attacks and sustained improvement in lung function among the children who participated in the yearlong add-on study.
Patients With Moderate-to-Severe Atopic Dermatitis Experience Impaired QOL, Feel Disease Burden
September 07, 2022
A national study in Germany identified the baseline characteristics of patients with moderate-to-severe atopic dermatitis (AD) to understand how they are usually treated with Dupixent in the real world.
Management of EoE May Need to Be Rethought to Reduce Treatment Burden, Impact on Quality of Life
September 02, 2022
Therapeutic goals of reducing eosinophil counts below a certain level in eosinophilic esophagitis (EoE) has a marginal benefit for the impact on quality of life and treatment burden.
Patients Maintain Controlled AD Even After Reduction of Dupixent Dose
August 10, 2022
Patients with persistently controlled atopic dermatitis (AD) who had their doses reduced were able to maintain their low disease activity.